LDL-C Targets in Secondary Prevention

How Low Should We Go?

Karim Bayoumy, Mohammed Gaber, Preethi Mani, Rishi Puri, Eoin Donnellan, Leslie Cho, Donald Clark, Seth Martin, Mohamed B. Elshazly

Research output: Contribution to journalReview article

Abstract

Purpose of Review: The benefits of lowering low-density lipoprotein cholesterol (LDL-C), mainly using high-intensity statin therapy, and its impact on decreasing the recurrence of atherosclerotic cardiovascular disease (ASCVD) in secondary prevention has been well established. With the advent of non-statin medications, particularly PCSK-9 inhibitors, which can lower LDL-C to very low levels not seen before, it is important to answer some important questions regarding LDL-C lowering and the uses of these medications in clinical practice: how low should we go with LDL-C reduction? Is there a threshold beyond which lower LDL-C is not associated with any benefit and possibly harm? Does the benefit derived from more aggressive LDL-C lowering justify the cost of additional therapies? Recent Findings: Our review has found overwhelming evidence to support the conclusion that lower achieved LDL-C levels correlate with a decreased burden of atherosclerosis and better clinical outcomes in secondary prevention. The concern for adverse effects with very low LDL-C levels is not backed by the literature, and side effects appear to be medication-specific. There still remains a question of the cost-effectiveness of some non-statin therapies particularly PCSK9 inhibitors, in spite of recent price decreases, and whether the benefit is worth the cost. Summary: It is prudent to always pursue an individualized patient-level approach to LDL-C lowering that considers the patient’s global cardiovascular risk, their side effect profile, and the cost-effectiveness of therapies in order to derive maximal benefit from aggressive lipid lowering.

Original languageEnglish (US)
Article number23
JournalCurrent Cardiovascular Risk Reports
Volume13
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Secondary Prevention
LDL Cholesterol
Cost-Benefit Analysis
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Costs and Cost Analysis
VLDL Cholesterol
Therapeutics
Atherosclerosis
Cardiovascular Diseases
Lipids
Recurrence

Keywords

  • Adverse effects
  • Clinical guidelines
  • LDL lowering
  • PCSK9 inhibitors
  • Secondary prevention

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Bayoumy, K., Gaber, M., Mani, P., Puri, R., Donnellan, E., Cho, L., ... Elshazly, M. B. (2019). LDL-C Targets in Secondary Prevention: How Low Should We Go? Current Cardiovascular Risk Reports, 13(8), [23]. https://doi.org/10.1007/s12170-019-0619-8

LDL-C Targets in Secondary Prevention : How Low Should We Go? / Bayoumy, Karim; Gaber, Mohammed; Mani, Preethi; Puri, Rishi; Donnellan, Eoin; Cho, Leslie; Clark, Donald; Martin, Seth; Elshazly, Mohamed B.

In: Current Cardiovascular Risk Reports, Vol. 13, No. 8, 23, 01.08.2019.

Research output: Contribution to journalReview article

Bayoumy, K, Gaber, M, Mani, P, Puri, R, Donnellan, E, Cho, L, Clark, D, Martin, S & Elshazly, MB 2019, 'LDL-C Targets in Secondary Prevention: How Low Should We Go?', Current Cardiovascular Risk Reports, vol. 13, no. 8, 23. https://doi.org/10.1007/s12170-019-0619-8
Bayoumy, Karim ; Gaber, Mohammed ; Mani, Preethi ; Puri, Rishi ; Donnellan, Eoin ; Cho, Leslie ; Clark, Donald ; Martin, Seth ; Elshazly, Mohamed B. / LDL-C Targets in Secondary Prevention : How Low Should We Go?. In: Current Cardiovascular Risk Reports. 2019 ; Vol. 13, No. 8.
@article{8120b3eaf895419092902789a378ddce,
title = "LDL-C Targets in Secondary Prevention: How Low Should We Go?",
abstract = "Purpose of Review: The benefits of lowering low-density lipoprotein cholesterol (LDL-C), mainly using high-intensity statin therapy, and its impact on decreasing the recurrence of atherosclerotic cardiovascular disease (ASCVD) in secondary prevention has been well established. With the advent of non-statin medications, particularly PCSK-9 inhibitors, which can lower LDL-C to very low levels not seen before, it is important to answer some important questions regarding LDL-C lowering and the uses of these medications in clinical practice: how low should we go with LDL-C reduction? Is there a threshold beyond which lower LDL-C is not associated with any benefit and possibly harm? Does the benefit derived from more aggressive LDL-C lowering justify the cost of additional therapies? Recent Findings: Our review has found overwhelming evidence to support the conclusion that lower achieved LDL-C levels correlate with a decreased burden of atherosclerosis and better clinical outcomes in secondary prevention. The concern for adverse effects with very low LDL-C levels is not backed by the literature, and side effects appear to be medication-specific. There still remains a question of the cost-effectiveness of some non-statin therapies particularly PCSK9 inhibitors, in spite of recent price decreases, and whether the benefit is worth the cost. Summary: It is prudent to always pursue an individualized patient-level approach to LDL-C lowering that considers the patient’s global cardiovascular risk, their side effect profile, and the cost-effectiveness of therapies in order to derive maximal benefit from aggressive lipid lowering.",
keywords = "Adverse effects, Clinical guidelines, LDL lowering, PCSK9 inhibitors, Secondary prevention",
author = "Karim Bayoumy and Mohammed Gaber and Preethi Mani and Rishi Puri and Eoin Donnellan and Leslie Cho and Donald Clark and Seth Martin and Elshazly, {Mohamed B.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1007/s12170-019-0619-8",
language = "English (US)",
volume = "13",
journal = "Current Cardiovascular Risk Reports",
issn = "1932-9520",
publisher = "Current Medicine Group",
number = "8",

}

TY - JOUR

T1 - LDL-C Targets in Secondary Prevention

T2 - How Low Should We Go?

AU - Bayoumy, Karim

AU - Gaber, Mohammed

AU - Mani, Preethi

AU - Puri, Rishi

AU - Donnellan, Eoin

AU - Cho, Leslie

AU - Clark, Donald

AU - Martin, Seth

AU - Elshazly, Mohamed B.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Purpose of Review: The benefits of lowering low-density lipoprotein cholesterol (LDL-C), mainly using high-intensity statin therapy, and its impact on decreasing the recurrence of atherosclerotic cardiovascular disease (ASCVD) in secondary prevention has been well established. With the advent of non-statin medications, particularly PCSK-9 inhibitors, which can lower LDL-C to very low levels not seen before, it is important to answer some important questions regarding LDL-C lowering and the uses of these medications in clinical practice: how low should we go with LDL-C reduction? Is there a threshold beyond which lower LDL-C is not associated with any benefit and possibly harm? Does the benefit derived from more aggressive LDL-C lowering justify the cost of additional therapies? Recent Findings: Our review has found overwhelming evidence to support the conclusion that lower achieved LDL-C levels correlate with a decreased burden of atherosclerosis and better clinical outcomes in secondary prevention. The concern for adverse effects with very low LDL-C levels is not backed by the literature, and side effects appear to be medication-specific. There still remains a question of the cost-effectiveness of some non-statin therapies particularly PCSK9 inhibitors, in spite of recent price decreases, and whether the benefit is worth the cost. Summary: It is prudent to always pursue an individualized patient-level approach to LDL-C lowering that considers the patient’s global cardiovascular risk, their side effect profile, and the cost-effectiveness of therapies in order to derive maximal benefit from aggressive lipid lowering.

AB - Purpose of Review: The benefits of lowering low-density lipoprotein cholesterol (LDL-C), mainly using high-intensity statin therapy, and its impact on decreasing the recurrence of atherosclerotic cardiovascular disease (ASCVD) in secondary prevention has been well established. With the advent of non-statin medications, particularly PCSK-9 inhibitors, which can lower LDL-C to very low levels not seen before, it is important to answer some important questions regarding LDL-C lowering and the uses of these medications in clinical practice: how low should we go with LDL-C reduction? Is there a threshold beyond which lower LDL-C is not associated with any benefit and possibly harm? Does the benefit derived from more aggressive LDL-C lowering justify the cost of additional therapies? Recent Findings: Our review has found overwhelming evidence to support the conclusion that lower achieved LDL-C levels correlate with a decreased burden of atherosclerosis and better clinical outcomes in secondary prevention. The concern for adverse effects with very low LDL-C levels is not backed by the literature, and side effects appear to be medication-specific. There still remains a question of the cost-effectiveness of some non-statin therapies particularly PCSK9 inhibitors, in spite of recent price decreases, and whether the benefit is worth the cost. Summary: It is prudent to always pursue an individualized patient-level approach to LDL-C lowering that considers the patient’s global cardiovascular risk, their side effect profile, and the cost-effectiveness of therapies in order to derive maximal benefit from aggressive lipid lowering.

KW - Adverse effects

KW - Clinical guidelines

KW - LDL lowering

KW - PCSK9 inhibitors

KW - Secondary prevention

UR - http://www.scopus.com/inward/record.url?scp=85067518877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067518877&partnerID=8YFLogxK

U2 - 10.1007/s12170-019-0619-8

DO - 10.1007/s12170-019-0619-8

M3 - Review article

VL - 13

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

SN - 1932-9520

IS - 8

M1 - 23

ER -